Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial
Summary
Digoxin is the oldest drug in cardiovascular medicine, but its value in the current management of heart failure is unclear. Earlier studies have suggested that low-dose digoxin might be beneficial, but evidence from rigorous randomized clinical trials is lacking. In this double-blind, placebo-controlled trial (the DECISION trial), 1,001 patients with symptomatic chronic heart failure and a left ventricular ejection fraction of 50% or less were randomized to low-dose digoxin or placebo, wit
Content
# Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial
*Published: 2026 May 10*
Digoxin is the oldest drug in cardiovascular medicine, but its value in the
current management of heart failure is unclear. Earlier studies have suggested
that low-dose digoxin might be beneficial, but evidence from rigorous randomized
clinical trials is lacking. In this double-blind, placebo-controlled trial (the
DECISION trial), 1,001 patients with symptomatic chronic heart failure and a
left ventricular ejection fraction of 50% or less were randomized to low-dose
digoxin or placebo, with a target serum digoxin concentration of
0.5-0.9 ng ml-1. The mean age of the participants was 72 ± 9 years, 28% were
women and 29% had atrial fibrillation. The primary outcome was a composite of
total worsening heart failure events, defined as total hospitalizations or total
urgent hospital visits for worsening heart failure and cardiovascular mortality.
Over a median follow-up of 36.5 months, 238 primary-outcome events occurred in
131 of 500 patients in the digoxin group, and 291 primary-outcome events in 152
of 501 patients occurred in the placebo group (rate ratio 0.81; 95% confidence
interval (CI) 0.61-1.07, P = 0.133). The total number of worsening heart failure
events was 155 and 203 in the digoxin and placebo groups, respectively (rate
ratio 0.76, 95% CI 0.54-1.05) and cardiovascular mortality occurred in 83
patients (17%) and 88 (18%) in the digoxin and placebo groups, respectively
(hazard ratio 0.93, 95% CI 0.69-1.26). Low-dose digoxin was generally well
tolerated and safe, and results were similar between men and women. The results
of this trial indicate that in patients with heart failure and reduced or mildly
reduced ejection fraction, low-dose digoxin did not significantly reduce the
composite endpoint of total worsening heart failure events or cardiovascular
mortality. ClinicalTrials.gov registration: NCT03783429 .
DOI: 10.1038/s41591-026-04406-6